CFRX News and Press, ContraFect Corporation From 05/26/21

Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients treated under compassionate use in France warrant further study of the use o...

Contrafect (CFRX): Q1 GAAP EPS of -$0.18 beats by $0.11.Cash, cash equivalents and marketable securities of $87.2M.Press Release For further details see: Contrafect EPS beats by $0.11

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong financial position with cash and investments of $...

YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of lif...

YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of l...

YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of l...

Shares of ContraFect Corporation (NASDAQ:CFRX) traded today at $3.93, breaking its 52-week low. Approximately 3.2 million shares have changed hands today, as compared to an average 30-day volume of 2 million shares. In the past 52 weeks, ContraFect Corporation share prices are bracketed ...

ContraFect Corporation (NASDAQ:CFRX) traded today at a new 52-week low of $3.89. So far today approximately 3.2 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. ContraFect Corp is a cinical-stage biotechnology company which focuses on disco...

Shares of ContraFect Corporation (NASDAQ:CFRX) traded today at $4.18, breaking its 52-week low. This new low was reached on above average trading volume as 3.2 million shares traded hands, while the average 30-day volume is approximately 1.8 million shares. ContraFect Corporation (NASDAQ...

If you know what penny stocks are, you understand how risk plays a role. But you can’t expect uncapped gain potential from safe investments. The beauty of buying penny stocks, is having the ability to leverage less capital in exchange for a much larger gain percentage. Defined as...